IMMX Stock Price | Immix Biopharma Inc P/E, Revenue, EPS, & Forecasts

Immix Biopharma Inc • IMMX

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Immix Biopharma Inc

Ticker

IMMX

Trading on

NASDAQ

ISIN

US45258H1068

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.

Headquarters

11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064

Employees

Website

immixbio.com

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Metrics

BasicAdvanced

Market cap

$101M

P/E ratio

EPS

-$0.77

Dividend Yield

0.00%

Beta

0.33

Forward P/E ratio

EBIDTA

$-23.7M

Ex dividend date

Price & volume

Market cap

$101M

Average daily volume

0.8M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

Price to book

14.74

Earnings

EPS

-$0.77

EPS estimate (current quarter)

-$0.16

EPS estimate (next quarter)

-$0.16

EBITDA

$-23.7M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

0.33

52-week High

$4.05

52-week Low

$1.34

50-day moving average

$2.54

200-day moving average

$2.21

Short ratio

1.51

Short %

2.77%

Management effectiveness

ROE (TTM)

-162.04%

ROA (TTM)

-66.85%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

33M

Float

19.4M

Insiders %

35.71%

Institutions %

8.46%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 1 analysts.

Average price target

$8.00

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.24

-$0.16

-50.00%

Q3 • 24Missed

-$0.25

Q4 • 24Beat

-$0.15

-$0.23

34.78%

Q1 • 25Beat

-$0.22

-$0.21

-4.76%

Q2 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-4.5M

-∞%

Q1 • 25

$0M

$-6.6M

-∞%

Q2 • 25

NaN%

45.79%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$19.9M

$10.3M

51.77%

Q1 • 25

$15.6M

$11M

70.24%

Q2 • 25

-21.40%

6.64%

35.67%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-1.7M

$-0.1M

$0M

$-1.8M

Q1 • 25

$-5.3M

$-0.1M

$1.1M

$-5.4M

Q2 • 25

215.09%

88.49%

∞%

210.20%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Immix Biopharma Inc share?

Immix Biopharma Inc shares are currently traded for undefined per share.

How many shares does Immix Biopharma Inc have?

Immix Biopharma Inc currently has 33M shares.

Does Immix Biopharma Inc pay dividends?

No, Immix Biopharma Inc doesn't pay dividends.

What is Immix Biopharma Inc 52 week high?

Immix Biopharma Inc 52 week high is $4.05.

What is Immix Biopharma Inc 52 week low?

Immix Biopharma Inc 52 week low is $1.34.

What is the 200-day moving average of Immix Biopharma Inc?

Immix Biopharma Inc 200-day moving average is $2.21.

Who is Immix Biopharma Inc CEO?

The CEO of Immix Biopharma Inc is Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D..

How many employees Immix Biopharma Inc has?

Immix Biopharma Inc has 18 employees.

What is the market cap of Immix Biopharma Inc?

The market cap of Immix Biopharma Inc is $101M.

What is the P/E of Immix Biopharma Inc?

The current P/E of Immix Biopharma Inc is null.

What is the EPS of Immix Biopharma Inc?

The EPS of Immix Biopharma Inc is -$0.77.

What is the PEG Ratio of Immix Biopharma Inc?

The PEG Ratio of Immix Biopharma Inc is null.

What do analysts say about Immix Biopharma Inc?

According to the analysts Immix Biopharma Inc is considered a buy.